RESEARCH · GLOW BLEND · THE COMBINATION QUESTION
GLOW BLEND and the Combination Question: Interactions, Copper Chemistry and Multi-Peptide Stability Unknowns
PurixLab’s GLOW BLEND 70mg puts three research materials in one vial: BPC-157, TB-500 and GHK-Cu, labelled at 10mg, 10mg and 50mg. Our earlier articles cover a component overview and thymosin β4 actin sequestration. This article asks a narrower question: what has actually been tested about these molecules together, and what would a proper combination study have to measure? The blend is supplied for laboratory research use only, and nothing here describes effects of any PurixLab product.
What has actually been tested together
We found one controlled study that combined two of the three components. Bičer and colleagues randomised thirty-two rats with repaired Achilles tendons into four groups of eight: control, BPC-157, TB-500, and BPC-157 plus TB-500, with outcomes at four weeks [1]. The TB-500 group showed significantly higher maximum load to failure and lower Bonar scores; the TB-500 and combined groups had lower Movin scores; and combined BPC-157 and TB-500 treatment did not confer additional benefits compared with either agent alone [1]. The authors call it an exploratory study and suggest the absence of additive effects may reflect convergence on shared downstream pathways, a hypothesis that still requires experimental confirmation [1].
As of 2026-10-17 we found no PubMed-indexed study testing BPC-157, TB-500 and GHK-Cu as a single three-component mixture. Multi-signal designs exist elsewhere: in a synthetic cryogel model, combining RGD with GHK and then with copper(II) increased endothelial-cell proliferation and angiogenesis-related cytokine production [2]. That work used immobilised, chemically modified peptides, so it illustrates how combinations can be studied rather than what this blend does. A 2026 sports-medicine review likewise notes that rigorous human safety data are scarce for unapproved peptides, including BPC-157, GHK-Cu, thymosin β4 and TB-500 [3].
First question: which molecule is “TB-500”?
Doping-control chemists identified the key ingredient of a veterinary product sold as TB-500 as N-acetylated LKKTETQ, the 17–23 segment of thymosin β4, not the full-length protein [4,5]. In rats and in vitro systems, Ac-LK was the main early metabolite, Ac-LKK was detected up to 72 hr, and only the Ac-LKKTE fragment showed significant wound-healing activity in fibroblasts [6]. By contrast, the tendon study above describes its TB-500 as synthetic thymosin beta-4 [1]. Before any interaction can be interpreted, a blend study must confirm which sequence is actually present and track its fragments.
GHK-Cu is chemically active, not an inert passenger
Potentiometric work showed that copper(II) and GHK form multiple species across pH 3.5 to 10.6, and that GHK competes with albumin for copper: at equimolar albumin and peptide, about 42% of the copper was bound to the peptide [7]. Structural studies found that Cu(II)-GHK in solution uses three nitrogen ligands, leaving a labile fourth position that can form ternary complexes with glycine or histidine, and that copper exchanges rapidly between GHK molecules [8]. Human serum albumin forms ternary Cu(GHK) complexes through histidine side chains, one at His3 with a conditional binding constant of 2900 M-1 at pH 7.4 [9]. GHK-Cu also shows laccase-like catalytic activity toward phenolic substrates [10].
None of these studies included BPC-157 or TB-500. They do show that a copper complex sharing a vial with other peptides could, in principle, exchange ligands or participate in redox chemistry, and that nobody has measured whether it does in this format.
Oxidation: why it matters for a mixture
Metal-catalysed oxidation is a classic peptide-degradation route. In an ascorbate/copper(II)/oxygen system, histidine-containing model peptides degraded quickly: at pH 7.4 only 4% of one peptide remained after 7 hours, catalase and EDTA were stabilising, and hydrogen peroxide, Cu(I) and superoxide were deduced intermediates [11]. Thymosin β4 carries a methionine at position 6; its sulfoxide inhibited actin polymerisation about 20 times less than the native peptide [12], and in a separate study the oxidised form, but not the native one, inhibited carrageenin-induced paw oedema in mice [13]. Oxidation can therefore change what a β-thymosin does, so a blend containing full-length thymosin β4 alongside copper would need sulfoxide monitoring. A 17–23 fragment would not contain that residue, which again makes identity the first variable.
Stability of each component alone
A GHK-Cu preformulation study found the peptide susceptible to hydrolytic cleavage under basic and oxidative stress, yet stable in water and pH 4.5–7.4 buffers for at least two weeks at 60 °C; histidine was one of three key degradation products, and stability fell in the presence of a negatively charged lipid [14]. For BPC-157, a 2026 biopharmaceutical review reports no pharmaceutical-grade formulation and no formal excipient-compatibility studies [15], while a rat and dog study found an elimination half-life under 30 min and rapid metabolism into small peptide fragments [16]. No published study has examined how the three behave when co-lyophilised and stored together.
What a combination study would need to measure
- A factorial design. Each component alone, each pair, the triple and vehicle, across full concentration-response ranges. Synergy claims need an explicit reference model such as Loewe additivity or Bliss independence [17]; in the Chou–Talalay framework a combination index of 1 means additive, below 1 synergy and above 1 antagonism [18].
- Identity and fragments. Confirmation of which TB-500 sequence is present and tracking of its metabolites [6,5].
- Copper chemistry. Copper speciation, ligand exchange and any redox activity in the presence of the other peptides [7,8,9].
- Oxidative stability. Methionine-sulfoxide and histidine-oxidation monitoring during storage and dissolution [12,11].
- Blend ADME. There is no combined pharmacokinetic study; each component’s profile is characterised separately or not at all [16,15].
Put simply, the combination question is still open. One two-component tendon study found no additive benefit [1], and the chemistry literature shows reasons a copper-peptide mixture could interact that nobody has tested in this exact format.
GLOW BLEND 70mg at PurixLab
GLOW BLEND 70mg: a labelled lyophilized research vial combining BPC-157, TB-500 and GHK-Cu (10mg + 10mg + 50mg, 70mg total per vial), C$136 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/glow-blend-70mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PubMed 42542926 · doi:10.52312/jdrs.2026.2951
- Zoughaib M, Luong D, Garifullin R, et al. Enhanced angiogenic effects of RGD, GHK peptides and copper (II) compositions in synthetic cryogel ECM model. Mater Sci Eng C Mater Biol Appl. 2021;120:111660. PubMed 33545827 · doi:10.1016/j.msec.2020.111660
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PubMed 41966639 · doi:10.1007/s40279-026-02437-0
- Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PubMed 23084823 · doi:10.1016/j.chroma.2012.09.043
- Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-8. PubMed 22962027 · doi:10.1002/dta.1402
- Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024;1235:124033. PubMed 38382158 · doi:10.1016/j.jchromb.2024.124033
- Lau SJ, Sarkar B. The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J. 1981;199(3):649-56. PubMed 7340824 · PMC1163421 · doi:10.1042/bj1990649
- Hureau C, Eury H, Guillot R, et al. X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. Chemistry. 2011;17(36):10151-60. PubMed 21780203 · doi:10.1002/chem.201100751
- Bossak-Ahmad K, Bal W, Frączyk T, et al. Ternary Cu2+ Complexes of Human Serum Albumin and Glycyl-l-histidyl-l-lysine. Inorg Chem. 2021;60(22):16927-16931. PubMed 34730942 · doi:10.1021/acs.inorgchem.1c03084
- Chen JS, Zhu H, Chai TQ, et al. The Laccase-like Property of GHK-Cu and Its Applications in Colorimetric Sensing of Phenolic Compounds. Biosensors (Basel). 2026;16(4):217. PubMed 42041438 · PMC13115362 · doi:10.3390/bios16040217
- Khossravi M, Borchardt RT. Chemical pathways of peptide degradation: IX. Metal-catalyzed oxidation of histidine in model peptides. Pharm Res. 1998;15(7):1096-102. PubMed 9688066 · doi:10.1023/a:1011946631197
- Heintz D, Reichert A, Mihelic-Rapp M, et al. The sulfoxide of thymosin beta 4 almost lacks the polymerization-inhibiting capacity for actin. Eur J Biochem. 1994;223(2):345-50. PubMed 8055902 · doi:10.1111/j.1432-1033.1994.tb19000.x
- Young JD, Lawrence AJ, MacLean AG, et al. Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med. 1999;5(12):1424-7. PubMed 10581087 · doi:10.1038/71002
- Badenhorst T, Svirskis D, Wu Z. Physicochemical characterization of native glycyl-l-histidyl-l-lysine tripeptide for wound healing and anti-aging: a preformulation study for dermal delivery. Pharm Dev Technol. 2016;21(2):152-60. PubMed 25384620 · doi:10.3109/10837450.2014.979944
- Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. PubMed 42198317 · PMC13210877 · doi:10.3390/pharmaceutics18050625
- He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. PubMed 36588717 · PMC9794587 · doi:10.3389/fphar.2022.1026182
- Roell KR, Reif DM, Motsinger-Reif AA. An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines. Front Pharmacol. 2017;8:158. PubMed 28473769 · PMC5397413 · doi:10.3389/fphar.2017.00158
- Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440-6. PubMed 20068163 · doi:10.1158/0008-5472.CAN-09-1947